Arsenic trioxide is under clinical development by Syros Pharmaceuticals and currently in Phase I for Myeloproliferative Disorders. According to GlobalData, Phase I drugs for Myeloproliferative Disorders have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Arsenic trioxide’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Arsenic trioxide overview
Arsenic trioxide is under development for the treatment of relapsed and refractory acute myelocytic leukemia (AML) including acute promyelocytic leukemia (APL), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), mantle cell lymphoma (MCL) and myeloproliferative neoplasm. It is administered orally. The drug candidate acts by preventing the production of DNA, which is necessary for leukaemia cells to grow.
Syros Pharmaceuticals overview
Syros Pharmaceuticals (Syros) is a biopharmaceutical company that develops medicines for the treatment of cancer, immune-mediated diseases, and other diseases. The company offers its pipeline products under clinical trials including Tamibarotene, an oral potent and selective RARa agonist, SY-2101, a arsenic trioxide (ATO) and SY-5609, a highly selective and potent oral inhibitor. Syors products are used to treat the patients with acute myeloid leukemia and myelodysplastic syndrome (MDS); acute promyelocytic leukemia, pancreatic cancer and BRAF-mutant colorectal cancer. It also provides gene regulation, new medicines development, proprietary drug development platform, and integrated gene control assay technologies. The company’s gene control platform identifies novel gene control targets linked to genomically defined patient populations and drugging gene control targets. It partners with other biopharmaceutical companies to extend the potential of our gene control platform across multiple therapeutic areas and diseases. Syros is headquartered in Cambridge, Massachusetts, the US
For a complete picture of Arsenic trioxide’s drug-specific PTSR and LoA scores, buy the report here.